Prostatype Genomics
Prostatype Genomics publishes Annual Report for 2023
Prostatype Genomics AB today publishes the Annual Report for the financial year of 2023. The Annual Report (Swedish) is attached as a PDF and is available on the company's webpage: www.prostatypegenomics.com
The English version of the Annual Report will be available to downloaded from the company’s webpage within shortly.
For more information, please contact:
Fredrik Rickman (previously Persson), CEO Prostatype Genomics AB
Telephone: +46 (0) 73 049 77 01
e-mail: fredrik.persson@prostatypegenomics.com
About Prostatype Genomics AB
Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB. The Company’s Certified Adviser is Carnegie Investment Bank AB.
| Datum | 2024-04-25, kl 13:31 |
| Källa | MFN |
Investera som eToros bästa investerare! Med eToros CopyTrader™, kan du automatiskt kopiera andra investerares beslut. Hitta investerare som du tror på och kopiera deras investeringar i realtid. Inga extra avgifter tas ut för funktionen.